Caxton Associates (New York)’s MetLife MET Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$280K Hold
3,420
0.01% 418
2024
Q3
$282K Hold
3,420
0.01% 448
2024
Q2
$240K Buy
+3,420
New +$244K 0.01% 421
2022
Q2
Sell
-7,851
Closed -$552K 669
2022
Q1
$552K Sell
7,851
-7,994
-50% -$540K 0.04% 224
2021
Q4
$990K Buy
+15,845
New +$994K 0.1% 108
2020
Q4
Sell
-7,750
Closed -$288K 253
2020
Q3
$288K Sell
7,750
-1,631
-17% -$61.9K 0.03% 201
2020
Q2
$343K Sell
9,381
-37,642
-80% -$1.31M 0.03% 218
2020
Q1
$1.44M Buy
+47,023
New +$2.09M 0.26% 31
2019
Q4
Sell
-20,029
Closed -$945K 492
2019
Q3
$945K Buy
+20,029
New +$955K 0.19% 46
2018
Q3
Sell
-16,697
Closed -$728K 493
2018
Q2
$728K Buy
+16,697
New +$778K 0.04% 203
2018
Q1
Sell
-23,945
Closed -$1.21M 391
2017
Q4
$1.21M Buy
+23,945
New +$1.26M 0.06% 182
2014
Q4
Sell
-44,880
Closed -$2.15M 165
2014
Q3
$2.15M Buy
+44,880
New +$2.18M 0.07% 148

Other funds holding MET

Caxton Associates (New York)'s MET Position: Q4 2024 in Review

Caxton Associates (New York) held its MetLife (MET) position steady in Q4 2024 at 3,420 shares worth $280K. The position accounts for 0.01% of the portfolio, ranked #418.

Caxton Associates (New York) first reported a position in MET in Q3 2014 and has held it in 12 quarters since. The position peaked at $2.15M in Q3 2014. 1,405 funds tracked by Wall St. Rank hold MET as of Q4 2024.

  • Caxton Associates (New York) held 3,420 shares of MetLife worth $280K as of Q4 2024.
  • Caxton Associates (New York) left its MetLife share count unchanged in Q4 2024.
  • MetLife made up 0.01% of Caxton Associates (New York)'s portfolio in Q4 2024, its #418 holding.
  • Caxton Associates (New York) first reported a position in MetLife in Q3 2014 and has held it in 12 quarters since.
  • Caxton Associates (New York)'s MetLife position peaked at $2.15M in Q3 2014.
  • 1,405 funds tracked by Wall St. Rank held MetLife as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.